Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp. is a fully integrated biopharmaceutical company that develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra, which are used for the treatment of acute migraine with or without aura in adults. Tonix Pharmaceuticals Holding Corp. is developing several product candidates, including TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for cocaine intoxication; and TNX-1500, an Fc-modified humanized monoclonal antibody to prevent kidney transplant rejection and treat autoimmune conditions. Other development programs include TNX-4800, a humanized monoclonal antibody for the seasonal prevention of Lyme disease; TNX-2900, an intranasal oxytocin potentiated with magnesium for Prader-Willi syndrome; and TNX-1900, an intranasal potentiated oxytocin for binge eating disorder, adolescent obesity, bone health in pediatric autism, and arginine-vasopressin deficiency. The company is also developing TNX-801, a live horsepox vaccine for the prevention of smallpox and mpox; TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45 for the treatment or prevention of viral disease; TNX-4900, a highly selective small-molecule Sigma-1 receptor antagonist for neuropathic pain; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for gastric and colorectal cancers; and TNX-1800 and TNX-1850, live modified horsepox vaccines for the prevention of COVID. The company was founded in 2007 and is based in Berkeley Heights, New Jersey.